These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 6591221)
61. Beyond the therapeutic window: a case presentation. Schulz SC; Butterfield L; Garicano M; Narasimhachari N; Friedel RO J Clin Psychiatry; 1984 May; 45(5):223-5. PubMed ID: 6725212 [TBL] [Abstract][Full Text] [Related]
62. Serum prolactin as a correlate of clinical response to haloperidol. Van Putten T; Marder SR; Mintz J J Clin Psychopharmacol; 1991 Dec; 11(6):357-61. PubMed ID: 1770154 [TBL] [Abstract][Full Text] [Related]
63. Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. McEvoy JP; Hogarty GE; Steingard S Arch Gen Psychiatry; 1991 Aug; 48(8):739-45. PubMed ID: 1883257 [TBL] [Abstract][Full Text] [Related]
64. Haloperidol blood levels and effects in schizophrenia and schizoaffective disorder: a progress report. Volavka J; Cooper TB; Meisner M; Bitter I; Czobor P; Jaeger J Psychopharmacol Bull; 1990; 26(1):13-7. PubMed ID: 2371368 [TBL] [Abstract][Full Text] [Related]
65. Intensive treatment with haloperidol of treatment-resistant chronic schizophrenic patients. Hollister LE; Kim DY Am J Psychiatry; 1982 Nov; 139(11):1466-8. PubMed ID: 7137396 [TBL] [Abstract][Full Text] [Related]
66. Lack of correlation between the steady-state plasma concentrations of haloperidol and risperidone. Yasui-Furukori N; Kondo T; Mihara K; Suzuki A; Inoue Y; De Vries R; Kaneko S J Clin Pharmacol; 2002 Oct; 42(10):1083-8. PubMed ID: 12362921 [TBL] [Abstract][Full Text] [Related]
68. Electric convulsive therapy (ECT) increases plasma and red blood cell haloperidol neuroleptic activities. Aoba A; Kakita Y; Yamaguchi N; Shido M; Shibata M; Kitani K; Hasegawa K Life Sci; 1983 Oct; 33(18):1797-803. PubMed ID: 6645778 [TBL] [Abstract][Full Text] [Related]
69. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses]. Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M Encephale; 1995; 21(6):417-24. PubMed ID: 8674466 [TBL] [Abstract][Full Text] [Related]
70. Red blood cell membrane dynamics in schizophrenia. I. Membrane fluidity. Yao JK; van Kammen DP Schizophr Res; 1994 Feb; 11(3):209-16. PubMed ID: 8193060 [TBL] [Abstract][Full Text] [Related]
71. Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients. Suzuki A; Otani K; Mihara K; Yasui N; Kaneko S; Inoue Y; Hayashi K Pharmacogenetics; 1997 Oct; 7(5):415-8. PubMed ID: 9352580 [No Abstract] [Full Text] [Related]
72. Serum level monitoring and therapeutic effect of haloperidol in schizophrenic patients. Moulin MA; Davy JP; Debruyne D; Andersson JC; Bigot MC; Camsonne R; Poilpré E Psychopharmacology (Berl); 1982; 76(4):346-50. PubMed ID: 6812109 [TBL] [Abstract][Full Text] [Related]
73. Dose-dependent reduced haloperidol/haloperidol ratios: influence of patient-related variables. Lane HY; Chang WH; Chang YC; Hu OY; Lin HN; Jann MW; Hu WH Psychiatry Res; 1997 Sep; 72(2):127-32. PubMed ID: 9335203 [TBL] [Abstract][Full Text] [Related]
74. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation]. Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I Encephale; 2005; 31(2):235-46. PubMed ID: 15959450 [TBL] [Abstract][Full Text] [Related]
75. Does a therapeutic window for plasma haloperidol exist?: Preliminary Chinese data. Potkin SG; Shen YC; Zhou DF; Pardes H; Shu L; Phelps B; Poland R Psychopharmacol Bull; 1985; 21(1):59-61. PubMed ID: 3983339 [No Abstract] [Full Text] [Related]
76. Plasma drug level and clinical response. Cooper TB; Volavka J; Czobor P J Clin Psychopharmacol; 1992 Apr; 12(2):134-6. PubMed ID: 1573036 [No Abstract] [Full Text] [Related]
77. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. Zhang XY; Zhou DF; Cao LY; Zhang PY; Wu GY; Shen YC J Clin Psychiatry; 2004 Jul; 65(7):940-7. PubMed ID: 15291683 [TBL] [Abstract][Full Text] [Related]
78. High doses of haloperidol in schizophrenia. A clinical, biochemical, and pharmacokinetic study. Zarifian E; Scatton B; Bianchetti G; Cuche H; Loo H; Morselli PL Arch Gen Psychiatry; 1982 Feb; 39(2):212-5. PubMed ID: 7065833 [TBL] [Abstract][Full Text] [Related]
79. Neuroleptics in the treatment of aggressive challenging behaviour for people with intellectual disabilities: a randomised controlled trial (NACHBID). Tyrer P; Oliver-Africano P; Romeo R; Knapp M; Dickens S; Bouras N; Ahmed Z; Cooray S; Deb S; Murphy D; Hare M; Meade M; Reece B; Kramo K; Bhaumik S; Harley D; Regan A; Thomas D; Rao B; Karatela S; Lenôtre L; Watson J; Soni A; Crawford M; Eliahoo J; North B Health Technol Assess; 2009 Apr; 13(21):iii-iv, ix-xi, 1-54. PubMed ID: 19397849 [TBL] [Abstract][Full Text] [Related]
80. Haloperidol plasma levels and acute clinical change in schizophrenia. Coryell W; Kelly M; Perry PJ; Miller DD J Clin Psychopharmacol; 1990 Dec; 10(6):397-402. PubMed ID: 2286709 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]